For instance, we know that in non-GCB DLBCL there is high expression of target genes of the nuclear factor (NF)-κB transcription factors, with activity of the NF-κB pathway being implicated in the poor prognosis of these patients [11]. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.